Dibenzofuranylethylamines as 5-HT_2A/2C Receptor Agonists

Area of Science:

• Medicinal Chemistry
• Neuropharmacology
• Molecular Biology

Background:

• Human serotonin 5-HT₂ receptor subtypes share high sequence identity in their ligand-binding domains.
• Many current agonists lack selectivity between 5-HT_2A and 5-HT_2C receptors, despite differing pharmacological outcomes.
• Selective agonists for 5-HT_2C receptors are of significant therapeutic interest for conditions like schizophrenia and substance abuse.

Purpose of the Study:

• To synthesize novel phenethylamine analogs with improved selectivity for serotonin receptor subtypes.
• To investigate the structural basis for selectivity between 5-HT_2A and 5-HT_2C receptors using molecular docking.
• To identify potential drug candidates for treating central nervous system disorders.

Main Methods:

• Synthesis of five phenethylamine analogs featuring a dibenzo[b,d]furan moiety.
• Evaluation of receptor selectivity using binding assays.
• Molecular docking studies of the most potent compound (compound 5) into 5-HT_2A and 5-HT_2C receptor crystal structures.

Main Results:

• Two synthesized analogs demonstrated over 70-fold selectivity for the 5-HT_2C receptor.
• Molecular docking revealed that a single amino acid difference (Ala222^5.46 in 5-HT_2C vs. Ser242^5.46 in 5-HT_2A) underlies compound 5's selectivity.
• This residue difference disrupts key interactions (π-π stacking and hydrogen bonding) in the 5-HT_2A receptor binding pocket.

Conclusions:

• The residue at position 5.46 plays a critical role in determining ligand selectivity between 5-HT_2A and 5-HT_2C receptors.
• The identified dibenzofuran analogs represent promising leads for developing selective 5-HT_2C receptor agonists.
• Further exploration of the 5.46 residue's impact could guide the design of novel therapeutics for neurological and psychiatric conditions.